A retrospective chart review of patients with advanced melanoma receiving pembrolizumab therapy
Latest Information Update: 24 Jan 2017
Price :
$35 *
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions
- 24 Jan 2017 New trial record